RU2016134035A - УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА - Google Patents
УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА Download PDFInfo
- Publication number
- RU2016134035A RU2016134035A RU2016134035A RU2016134035A RU2016134035A RU 2016134035 A RU2016134035 A RU 2016134035A RU 2016134035 A RU2016134035 A RU 2016134035A RU 2016134035 A RU2016134035 A RU 2016134035A RU 2016134035 A RU2016134035 A RU 2016134035A
- Authority
- RU
- Russia
- Prior art keywords
- polymer
- formula
- paragraphs
- compound
- replaced
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7016—Disaccharides, e.g. lactose, lactulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F120/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride, ester, amide, imide or nitrile thereof
- C08F120/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
- C08F120/10—Esters
- C08F120/34—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate
- C08F120/36—Esters containing nitrogen, e.g. N,N-dimethylaminoethyl (meth)acrylate containing oxygen in addition to the carboxy oxygen, e.g. 2-N-morpholinoethyl (meth)acrylate or 2-isocyanatoethyl (meth)acrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
- C08F2/00—Processes of polymerisation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
- C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
- C08G69/10—Alpha-amino-carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
- C08G69/48—Polymers modified by chemical after-treatment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/02—Food
- G01N33/04—Dairy products
- G01N33/06—Determining fat content, e.g. by butyrometer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Polymers & Plastics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Saccharide Compounds (AREA)
Claims (27)
1. Соединение формулы (I)
или формулы (II)
где Z представляет собой необязательно замещенный фенил, гетероарил, арилкарбонил или гетероарил метил.
2. Соединение по п, 1, характеризующееся формулой (I) или (II), отличающееся тем, что Z представляет собой незамещенный или замещенный фенил.
3. Соединение по п. 2, характеризующееся формулой (I) или (II), отличающееся тем, что Z представляет собой п-метоксифенил.
4. Соединение по п. 2, характеризующееся формулой (I), отличающееся тем, что Z представляет собой п-метоксифенил.
5. Соединение по п. 2, характеризующееся формулой (II), отличающееся тем, что Z представляет собой п-метоксифенил.
6. Полимер, содержащий множество заместителей формулы (I) и/или формулы (II),
где Z представляет собой линкер, связывающий указанный заместитель с полимерным остовом.
7. Полимер по п. 6, отличающийся тем, что полимерный остов представляет собой полимер α-аминокислоты, полимер или сополимер акриловой кислоты или метакриловой кислоты, или сополимер N-винил-2-пирролидона и винилового спирта.
8. Полимер по п. 6, отличающийся тем, что полимерный остов представляет собой полимер α-аминокислоты, причем указанная α-аминокислота представляет собой лизин, глутаминовую кислоту или аспарагиновую кислоту.
9. Полимер по п. 6, отличающийся тем, что полимерный остов представляет собой полилизин.
10. Полимер по п, 7, отличающийся тем, что молекулярная масса указанного полимерного остова составляет от 1000 кДа до 300000 кДа.
11. Полимер по любому из пп. 6-10, отличающийся тем, что линкер Z представляет собой арил, гетероарил, арил-низший алкил, арилкарбонил или гетероарилметил, причем арил или гетероарил замещены алкиленом, содержащим от 3 до 25 атомов углерода, связанный с полимером, причем необязательно
(a) один или более атомов углерода алкиленовой группы заменен на азот, несущий атом водорода, и один из соседних атомов углерода замещен оксогруппой, обеспечивая амидную функциональную группу -NH-CO-; и/или
(b) один или более атомов углерода алкиленовой группы заменен на кислород;
(c) один или более атомов углерода алкиленовой группы заменен на серу; и/или
(d1) концевой атом углерода, связанный с полимером, замещен оксогруппой; или
(d2) концевой атом углерода, связанный с полимером, заменен -NH-.
12. Полимер по любому из пп. 6-10, отличающийся тем, что относительная молекулярная масса полимерного остова по отношению к дисахариду формулы (I) и/или (II) составляет от 10:1 до 1:1,5.
13. Фармацевтическая композиция, содержащая соединение формулы (I) или (II) по любому из пп. 1-5 или полимер по любому из пп. 6-12.
14. Диагностический набор, содержащий соединение формулы (I) или (II) по любому из пп. 1-5 или полимер по любому из пп. 6-12.
15. Применение соединения формулы (I) или (II) по любому из пп. 1-5 или полимера по любому из пп. 6-12 для диагностики анти-MAG нейропатии.
16. Способ лечения анти-MAG нейропатии, включающий введение соединения формулы (I) или (II) по любому из пп. 1-5 или полимера по любому из пп. 6-12 в количестве, эффективном против указанного заболевания, теплокровному животному, нуждающемуся в таком лечении.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14159528.0 | 2014-03-13 | ||
| EP14159528 | 2014-03-13 | ||
| PCT/EP2015/055140 WO2015136027A1 (en) | 2014-03-13 | 2015-03-12 | Carbohydrate ligands that bind to igm antibodies against myelin-associated glycoprotein |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| RU2016134035A true RU2016134035A (ru) | 2018-04-13 |
| RU2016134035A3 RU2016134035A3 (ru) | 2018-10-25 |
| RU2760005C2 RU2760005C2 (ru) | 2021-11-22 |
Family
ID=50241299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2016134035A RU2760005C2 (ru) | 2014-03-13 | 2015-03-12 | УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА |
Country Status (22)
| Country | Link |
|---|---|
| US (4) | US9994605B2 (ru) |
| EP (2) | EP3116887B1 (ru) |
| JP (1) | JP6502374B2 (ru) |
| KR (1) | KR20160132034A (ru) |
| CN (2) | CN106103461B (ru) |
| AU (2) | AU2015228870B2 (ru) |
| CA (1) | CA2940579A1 (ru) |
| CY (1) | CY1124344T1 (ru) |
| DK (1) | DK3116887T3 (ru) |
| ES (1) | ES2865148T3 (ru) |
| HR (1) | HRP20210562T1 (ru) |
| HU (1) | HUE054034T2 (ru) |
| IL (1) | IL247355B (ru) |
| LT (1) | LT3116887T (ru) |
| MX (1) | MX2016011859A (ru) |
| PL (1) | PL3116887T3 (ru) |
| PT (1) | PT3116887T (ru) |
| RS (1) | RS61722B1 (ru) |
| RU (1) | RU2760005C2 (ru) |
| SG (1) | SG11201607484RA (ru) |
| SI (1) | SI3116887T1 (ru) |
| WO (1) | WO2015136027A1 (ru) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3116887T3 (da) | 2014-03-13 | 2021-04-26 | Univ Basel | Carbonhydratligander, der binder til igm-antistoffer mod myelin-associeret glykoprotein |
| CN108026134A (zh) | 2015-09-16 | 2018-05-11 | 巴塞尔大学 | 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体 |
| WO2018167230A1 (en) * | 2017-03-15 | 2018-09-20 | Polyneuron Pharmaceuticals Ag | Glycopolymers sequestering carbohydrate-binding proteins |
| EP3715376A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of myasthenia gravis |
| EP3715375A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the prevention or treatment of pre-eclampsia |
| US11986536B2 (en) | 2019-03-23 | 2024-05-21 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| EP3715374A1 (en) | 2019-03-23 | 2020-09-30 | Ablevia biotech GmbH | Compound for the sequestration of undesirable antibodies in a patient |
| WO2022063879A1 (en) | 2020-09-23 | 2022-03-31 | Ablevia Biotech Gmbh | Compound for the sequestration of undesirable antibodies in a patient |
| JP2023542388A (ja) | 2020-09-23 | 2023-10-06 | アブレヴィア バイオテック ゲーエムベーハー | 第ｖｉｉｉ因子補充療法の有効性を増加させるための化合物 |
| AU2021347583A1 (en) | 2020-09-23 | 2023-05-25 | Ablevia Biotech Gmbh | Compound for increasing efficacy of viral vectors |
| CA3192740A1 (en) | 2020-09-23 | 2022-03-31 | Oskar SMRZKA | Compound for the prevention or treatment of autoantibody-mediated conditions |
| TW202228784A (zh) | 2020-09-23 | 2022-08-01 | 奧地利商艾柏力維亞生技有限公司 | 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物 |
| CN116710143A (zh) | 2020-09-24 | 2023-09-05 | 艾柏力维亚生技有限公司 | 用于预防或治疗重症肌无力的化合物 |
| WO2023180502A1 (en) | 2022-03-24 | 2023-09-28 | Ablevia Biotech Gmbh | Compound for increasing efficacy of oncolytic viruses |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2811494B2 (ja) | 1990-03-14 | 1998-10-15 | 富士写真フイルム株式会社 | キトサンまたはキチン化合物を含有するハロゲン化銀写真感光材料およびこれを用いるハロゲン化銀写真感光材料の処理方法 |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| JPH07502011A (ja) | 1991-06-10 | 1995-03-02 | グライカムド インコーポレイテッド | 免疫抑制性および寛容原性のオリゴ糖誘導体 |
| US6020140A (en) | 1991-08-09 | 2000-02-01 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
| WO1993003375A1 (en) | 1991-08-09 | 1993-02-18 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
| US5985578A (en) | 1991-08-09 | 1999-11-16 | Washington University | Autoantibodies and their targets in the diagnosis of peripheral neuropathies |
| WO1993003735A1 (en) | 1991-08-23 | 1993-03-04 | Alberta Research Council | Methods and compositions for attenuating antibody-mediated xenograft rejection in human recipients |
| EP0601417A3 (de) | 1992-12-11 | 1998-07-01 | Hoechst Aktiengesellschaft | Physiologisch verträglicher und physiologisch abbaubarer, Kohlenhydratrezeptorblocker auf Polymerbasis, ein Verfahren zu seiner Herstellung und seine Verwendung |
| CA2133772A1 (en) | 1993-11-19 | 1995-05-20 | Yuji Yamada | Method for assaying glycoconjugate and reagent thereof |
| US5783693A (en) | 1993-11-19 | 1998-07-21 | The Regents Of The University Of California | Methods for synthesizing sulfated disaccharide inhibitors of selectins |
| DE19526675A1 (de) | 1994-09-09 | 1996-03-14 | Herbert Prof Dr Wiegandt | Teststreifenanalyse zur Erfassung von autoallergen menschlichen Pathologien |
| FR2727117A1 (fr) | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
| DE19531346A1 (de) * | 1995-08-25 | 1997-02-27 | Gsf Forschungszentrum Umwelt | Arzneimittel zur Immuntherapie, enthaltend Antikörper, die spezifisch das MHCII-Antigen eines zu behandelnden Patienten erkennen |
| AU6858596A (en) * | 1995-08-25 | 1997-03-19 | Johns Hopkins University School Of Medicine, The | Compounds for stimulating nerve growth |
| AU1122897A (en) | 1995-11-13 | 1997-06-05 | Glycomed Incorporated | Novel oligosaccharide glycosides having mammalian immunosuppressive and tolerogenic properties |
| US6677164B1 (en) | 1995-11-21 | 2004-01-13 | Novartis Ag | Multivalent polymers, processes for their preparation, and their use for preparing biologically active compounds |
| US6491922B1 (en) | 1996-02-09 | 2002-12-10 | Cornell Research Foundation, Inc. | Methods and compounds for treating autoimmune and vascular disease |
| DE69835201T2 (de) | 1997-04-18 | 2007-06-14 | Novartis Ag | Neoglycoproteine |
| FR2762602B1 (fr) | 1997-04-28 | 1999-06-04 | Inst Nat Sante Rech Med | Moyens pour la detection precoce de pathologies auto-immunes inflammatoires |
| US6077681A (en) | 1997-06-30 | 2000-06-20 | Washington University | Diagnosis of motor neuropathy by detection of antibodies |
| JP2001515912A (ja) | 1997-09-05 | 2001-09-25 | グリシム オサケ ユキチュア | 合成二価ｓＬｅｘ含有ポリラクトサミン類および使用法 |
| ATE304865T1 (de) | 1998-04-15 | 2005-10-15 | Mayo Foundation | Hemmung xenoreaktiver antikörper |
| JP2002511494A (ja) | 1998-04-22 | 2002-04-16 | メルク エンド カムパニー インコーポレーテッド | 自己抗原断片、方法及びアッセイ |
| WO2000000516A1 (fr) | 1998-06-30 | 2000-01-06 | Mochida Pharmaceutical Co., Ltd. | Nouveau peptide lie par une chaine de sucres et similaire a la thrombomoduline |
| US6228598B1 (en) * | 1998-10-02 | 2001-05-08 | Washington University | Antibodies to heparan sulfate glycosaminoglycans in the diagnosis of polyneuropathies |
| CA2351146A1 (en) | 1998-11-16 | 2000-05-25 | Genetics Institute, Inc. | The cxc chemokine h174 and methods for preventing damage to the nervous system |
| US6399578B1 (en) | 1998-12-09 | 2002-06-04 | La Jolla Pharmaceutical Company | Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same |
| CA2353620A1 (en) | 1998-12-09 | 2000-06-15 | La Jolla Pharmaceutical Company | Methods and formulations for reducing circulating antibodies |
| WO2000050447A1 (en) | 1999-02-24 | 2000-08-31 | Acorda Therapeutics | Carbohydrate epitope mimic peptides and uses thereof |
| DE19930177B4 (de) | 1999-06-30 | 2007-02-08 | Nikolai Vladimirovich Bovin | Intermolekular assoziierende Verbindungen und deren Verwendung |
| KR20020047177A (ko) | 1999-09-21 | 2002-06-21 | 아피나 이문테히닉 게엠베하 | 확장성 심근질환을 유발하는 자동항체를 제거하기 위한펩티드 |
| US7332168B2 (en) | 2000-08-22 | 2008-02-19 | Micromet Ag | Composition for the elimination of autoreactive B-cells |
| WO2002018950A1 (en) | 2000-08-28 | 2002-03-07 | The Trustees Of Columbia University In The City Of New York | Detection of anti-glycolipid antibodies by latex agglutination assay |
| WO2002038592A2 (de) | 2000-11-08 | 2002-05-16 | Affina Immuntechnik Gmbh | Peptide, deren herstellung und verwendung zur bindung von immunglobulinen |
| US6730487B2 (en) | 2001-04-03 | 2004-05-04 | Trustees Of Columbia University In The City Of New York | Surface plasmon resonance biosensor for measurement of anti-glycolipid antibody levels in neuropathy |
| DE10127712A1 (de) | 2001-06-07 | 2002-12-19 | Torsten Witte | Anwendung von IgM-Antikörpern gegen dsDNA beim systemischen Lupus erythematodes mit Nephritis |
| DE60232077D1 (de) | 2001-06-29 | 2009-06-04 | Glykos Finland Oy | Verwendung mindestens einer glycoinhibitor-substanz gegen infektionskrankheiten |
| US7323440B2 (en) | 2002-02-13 | 2008-01-29 | Micromet Ag | De-immunized MOG (poly)peptide constructs |
| ES2297248T3 (es) | 2002-08-02 | 2008-05-01 | Glycominds Ltd. | Procedimiento para diagnosticar esclerosis multiple. |
| RU2303461C9 (ru) * | 2002-08-06 | 2007-12-27 | Глаксо Груп Лимитед | Антитела против миелин-ассоциированного гликопротеина (mag) |
| AR040778A1 (es) | 2002-08-06 | 2005-04-20 | Glaxo Group Ltd | Anticuerpos alterados o fragmentos funcionales que se unen a mag (glicoproteina asociada a mielina). |
| US7175989B2 (en) * | 2002-08-20 | 2007-02-13 | Alan Pestronk | Antibodies to trisulfated heparin disaccharide in painful sensory axonal neuropathy |
| US20040043431A1 (en) | 2002-08-29 | 2004-03-04 | Aristo Vojdani | Diagnosis of multiple sclerosis and other demyelinating diseases |
| US20030049692A1 (en) | 2002-09-16 | 2003-03-13 | Norman Latov | Detection of anti-glycolipid antibodies by latex agglutination assay |
| RU2389732C2 (ru) | 2003-01-06 | 2010-05-20 | Корикса Корпорейшн | Некоторые аминоалкилглюкозаминидфосфатные производные и их применение |
| WO2004065400A1 (en) | 2003-01-20 | 2004-08-05 | Glykos Finland Oy | Novel binding epitopes for helicobacter pylori and use thereof |
| EP2591786B1 (en) | 2003-10-16 | 2017-04-12 | Cancure Limited | Immunomodulating compositions and uses therefor |
| US20070258986A1 (en) | 2003-11-19 | 2007-11-08 | Govt of the US as represented by the secretary, | Targeted Delivery System for Bioactive Agents |
| US20050187171A1 (en) | 2003-11-19 | 2005-08-25 | Glycomimetics, Inc. | Glycomimetic antagonists for both E-and P-selectins |
| US7361644B2 (en) | 2003-11-19 | 2008-04-22 | Glycomimetics, Inc. | Specific antagonist for both E- and P-selectins |
| US20050272097A1 (en) | 2004-02-18 | 2005-12-08 | Emanuel Calenoff | Methods and compositions for detecting and treating autoimmune diseases |
| CA2557989C (en) | 2004-03-04 | 2013-04-23 | Progen Industries Limited | Sulfated oligosaccharide derivatives |
| EP1761550A2 (en) | 2004-05-26 | 2007-03-14 | California Institute of Technology | Small molecule stimulators of neuronal growth |
| CN101123990A (zh) | 2004-10-01 | 2008-02-13 | Mida科技有限公司 | 包含抗原和佐剂的纳米颗粒，和免疫原性结构 |
| AU2005291058B2 (en) | 2004-10-01 | 2011-09-29 | Midatech Limited | Nanoparticles comprising antigens and adjuvants and immunogenic structure |
| WO2006068720A2 (en) | 2004-11-12 | 2006-06-29 | The Brigham And Women's Hospital, Inc. | Hematopoietic cell selectin ligand polypeptides and methods of use thereof |
| US7884260B2 (en) | 2005-06-14 | 2011-02-08 | University Of Chicago | Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination |
| JP4619873B2 (ja) * | 2005-06-20 | 2011-01-26 | 独立行政法人産業技術総合研究所 | グルクロニル硫酸化２糖誘導体 |
| WO2010002478A2 (en) | 2008-07-03 | 2010-01-07 | University Of Georgia Research Foundation, Inc. | Glycopeptide and uses thereof |
| WO2007100699A2 (en) | 2006-02-24 | 2007-09-07 | Novartis Ag | Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions |
| WO2007120815A2 (en) | 2006-04-12 | 2007-10-25 | The Regents Of The University Of California | Methods for treating lymphocyte-associated disorders by modulation of siglec activity |
| GB0610350D0 (en) | 2006-05-25 | 2006-07-05 | Univ Liverpool | prevention and/or treatment of neuodegenerative disorders |
| US8420593B1 (en) | 2006-06-16 | 2013-04-16 | Landon C. G. Miller | Compositions and methods for regulating membrane potential |
| US20090175792A1 (en) | 2006-06-23 | 2009-07-09 | Glycomimetics, Inc. | Glycomimetic inhibitors of siglec-8 |
| JP5695317B2 (ja) | 2006-09-05 | 2015-04-01 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 抗体媒介性ニューロパシーを処置するための方法および組成物 |
| GB0622688D0 (en) | 2006-11-14 | 2006-12-27 | Diosamine Dev Corp | Novel compounds |
| US20080220988A1 (en) | 2007-03-07 | 2008-09-11 | Ada Technologies, Inc. | Preparing carbohydrate microarrays and conjugated nanoparticles |
| EP2842570B1 (en) | 2007-03-07 | 2020-05-06 | UTI Limited Partnership | Compositions and methods for the prevention and treatment of autoimmune conditions |
| WO2008151847A1 (en) | 2007-06-13 | 2008-12-18 | Max-Delbrück-Centrum für Molekulare Medizin | Autoantibody binding peptides and their use for the treatment of vascular diseases |
| EP2183251A1 (en) | 2007-08-02 | 2010-05-12 | Antisoma Ventures Limited | Indazole compounds for treating inflammatory disorders, demyelinating disorders and cancers |
| BRPI0820960B8 (pt) | 2007-12-05 | 2021-05-25 | Abivax | composição, composição farmacêutica, e uso da composição |
| WO2009102820A2 (en) | 2008-02-11 | 2009-08-20 | Government Of The U.S A., As Represented By The Secretary, Department Of Health And Human Services | Modified sugar substrates and methods of use |
| US9119866B2 (en) | 2008-04-08 | 2015-09-01 | Huiru Wang | Glycan-based drugs, therapies and biomarkers |
| AU2009234266B2 (en) | 2008-04-11 | 2015-08-06 | Tekmira Pharmaceuticals Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| US7981625B2 (en) | 2008-04-15 | 2011-07-19 | The Board Of Trustees Of The Leland Stanford Junior University | Prostate cancer glycan markers and autoantibody signatures |
| US20120190581A1 (en) | 2009-08-25 | 2012-07-26 | The Johns Hopkins University | Detection of Auto-Antibodies to Specific Glycans as Diagnostic Tests for Autoimmune Diseases |
| US20110105389A1 (en) * | 2009-10-30 | 2011-05-05 | Hoveyda Hamid R | Macrocyclic Ghrelin Receptor Antagonists and Inverse Agonists and Methods of Using the Same |
| GB0922066D0 (en) | 2009-12-17 | 2010-02-03 | Univ Belfast | Modulator |
| WO2011101870A1 (en) | 2010-02-22 | 2011-08-25 | Transgene Biotek Ltd. | Fusion proteins for the treatment of multiple sclerosis and other autoimmune diseases |
| WO2011156774A2 (en) | 2010-06-11 | 2011-12-15 | Sloan-Kettering Institute For Cancer Research | Multivalent glycopeptide constructs and uses thereof |
| CN103608032A (zh) | 2010-12-15 | 2014-02-26 | 基督科学教育协会 | 用于抑制免疫应答的方法 |
| WO2013044044A2 (en) | 2011-09-23 | 2013-03-28 | President And Fellows Of Harvard College | Methods of treating fatty liver disease with helminth-derived glycan-containing compounds |
| EP2698636A1 (en) | 2012-08-13 | 2014-02-19 | Fundació Institut d'Investigació Biomèdica de Bellvitge | Methods and reagents for prevention and/or treatment of transplant rejection |
| WO2014027302A1 (en) | 2012-08-16 | 2014-02-20 | Pfizer Inc. | Glycoconjugation processes and compositions |
| EP2727597A1 (en) | 2012-11-06 | 2014-05-07 | Centre National de la Recherche Scientifique (CNRS) | Glucose responsive hydrogel comprising pba-grafted hyaluronic acid (ha) |
| CN105324116B (zh) | 2013-04-26 | 2019-03-29 | 新加坡科技研究局 | 调适具有聚脯氨酸支架的生物聚合物的多价相互作用 |
| WO2015007326A1 (en) | 2013-07-18 | 2015-01-22 | Institut D'investigació Biomèdica De Bellvitge (Idibell) | Agents comprising a terminal alpha-galactosyl moiety for use in prevention and/or treatment of inflammatory diseases |
| WO2015116775A1 (en) | 2014-01-30 | 2015-08-06 | Trudeau Institute | Nanoparticles for immune stimulation |
| DK3116887T3 (da) | 2014-03-13 | 2021-04-26 | Univ Basel | Carbonhydratligander, der binder til igm-antistoffer mod myelin-associeret glykoprotein |
| CN108026134A (zh) | 2015-09-16 | 2018-05-11 | 巴塞尔大学 | 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体 |
-
2015
- 2015-03-12 DK DK15709483.0T patent/DK3116887T3/da active
- 2015-03-12 US US15/124,913 patent/US9994605B2/en active Active
- 2015-03-12 RS RS20210472A patent/RS61722B1/sr unknown
- 2015-03-12 CN CN201580013911.0A patent/CN106103461B/zh not_active Expired - Fee Related
- 2015-03-12 LT LTEP15709483.0T patent/LT3116887T/lt unknown
- 2015-03-12 JP JP2016557034A patent/JP6502374B2/ja not_active Expired - Fee Related
- 2015-03-12 HU HUE15709483A patent/HUE054034T2/hu unknown
- 2015-03-12 AU AU2015228870A patent/AU2015228870B2/en not_active Ceased
- 2015-03-12 SI SI201531580T patent/SI3116887T1/sl unknown
- 2015-03-12 PT PT157094830T patent/PT3116887T/pt unknown
- 2015-03-12 SG SG11201607484RA patent/SG11201607484RA/en unknown
- 2015-03-12 PL PL15709483T patent/PL3116887T3/pl unknown
- 2015-03-12 RU RU2016134035A patent/RU2760005C2/ru active
- 2015-03-12 MX MX2016011859A patent/MX2016011859A/es unknown
- 2015-03-12 EP EP15709483.0A patent/EP3116887B1/en active Active
- 2015-03-12 CA CA2940579A patent/CA2940579A1/en not_active Abandoned
- 2015-03-12 WO PCT/EP2015/055140 patent/WO2015136027A1/en active Application Filing
- 2015-03-12 KR KR1020167025624A patent/KR20160132034A/ko active IP Right Grant
- 2015-03-12 CN CN201910305446.8A patent/CN110204582A/zh active Pending
- 2015-03-12 ES ES15709483T patent/ES2865148T3/es active Active
- 2015-03-12 EP EP21157009.8A patent/EP3915999A1/en not_active Withdrawn
-
2016
- 2016-08-18 IL IL247355A patent/IL247355B/en active IP Right Grant
-
2018
- 2018-05-11 US US15/977,422 patent/US10662212B2/en not_active Expired - Fee Related
-
2019
- 2019-11-27 AU AU2019271964A patent/AU2019271964B2/en not_active Ceased
-
2020
- 2020-04-14 US US16/848,268 patent/US11220523B2/en active Active
-
2021
- 2021-04-08 HR HRP20210562TT patent/HRP20210562T1/hr unknown
- 2021-04-15 CY CY20211100331T patent/CY1124344T1/el unknown
- 2021-11-30 US US17/538,752 patent/US20220185838A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2016134035A (ru) | УГЛЕВОДНЫЕ ЛИГАНДЫ, КОТОРЫЕ СВЯЗЫВАЮТСЯ С IgM АНТИТЕЛАМИ ПРОТИВ МИЕЛИН-АССОЦИИРОВАННОГО ГЛИКОПРОТЕИНА | |
| BR112014016338A2 (pt) | polímeros de polioxazolina e processos para a sua preparação, conjugados destes polímeros e usos médicos dos mesmos | |
| RU2015119557A (ru) | Конъюгаты лекарственное вещество-белок | |
| RU2010140627A (ru) | Производные пирролидина | |
| RU2011105768A (ru) | Производные пиперидина в качестве ингибиторов jakз | |
| JP2012515776A5 (ru) | ||
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| JP2012523457A5 (ru) | ||
| CA2750413A1 (en) | Hydroxamic acid derivatives | |
| RU2015133450A (ru) | Соединения имидазопиридина и их применение | |
| EA200970446A1 (ru) | Связывающиеся с альбумином молекулы и их применение | |
| EA201070422A1 (ru) | Производные оксадиазола | |
| RU2010129238A (ru) | Применение производных изотиоцианата в качестве противомиеломных средств | |
| RU2016121713A (ru) | Композиция высоконасыщенного сополимерного каучука, содержащего нитрильные группы, и сшитый каучук | |
| RU2015148258A (ru) | Силоксановое соединение и способ его получения | |
| RU2020131276A (ru) | Терапевтические соединения и композиции | |
| RU2020108470A (ru) | Аддитивная композиция для культуральной среды, аддитивное соединение для культуральной среды и способ культивирования клеток или тканей с использованием этой композиции и соединения | |
| RU2020108634A (ru) | Аналоги карбамоилфенилаланинола и способы их применения | |
| WO2017105565A3 (en) | Compositions for therapeutics, targeted pet imaging and methods of their use | |
| EA201070250A1 (ru) | Противомикробный парентеральный состав | |
| RU2017122809A (ru) | Фармацевтический состав полимерного производного, содержащего камптотецин | |
| JP2014510741A5 (ru) | ||
| RU2014101953A (ru) | Агонисты протеинтирозинфосфатазы-1, содержащие домен гомологии-2 src, и способы лечения с применением указанных агонистов | |
| CA2797281A1 (en) | Aza-indole derivatives useful as modulators of faah | |
| RU2008130043A (ru) | Комбинация, включающая комбретастатин и противораковые средства |